2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoff, C. M. Articles by Shockley, T. R. Search for Related Content PubMed PubMed Citation Articles by Hoff, C. M. Articles by Shockley, T. R.

Peritoneal Dialysis in the 21st Century: The Potential of Gene Therapy

Baxter Healthcare Corporation, Renal Division, Scientific Affairs, McGaw Park, Illinois.

Correspondence to Dr. Catherine M. Hoff, Baxter Healthcare Corporation, Renal Division, MPGR-A2N, 1620 Waukegan Road, McGaw Park, IL 60085. Phone: 847-473-6227; Fax: 847-473-6902; E-mail: Cathy_Hoff{at}baxter.com

Abstract

ABSTRACT. One of the greatest biotechnologic advances of the last 25 yr is genetic engineering—the ability to identify and isolate individual genes and transfer genetic elements between cells. Genetic engineering forms the basis of a unique biotechnology platform called gene therapy: an approach to treating disease through genetic manipulation. It is becoming clear that during peritoneal dialysis, the peritoneal membrane undergoes various structural and functional changes that compromise the dialyzing efficiency of the membrane and eventually lead to membrane failure. A gene therapy strategy based on genetic modification of the peritoneal membrane could improve the practice of peritoneal dialysis through the production of proteins that would be of therapeutic value in preventing membrane damage and preserving its dialyzing capacity. The peritoneal membrane can be genetically modified by either ex vivo or in vivo gene transfer strategies with a variety of potentially therapeutic genes, including those for anti-inflammatory cytokines, fibrinolytic factors, and antifibrotic molecules. These genes could be administered either on an acute basis, such as in response to peritonitis, or on an intermittent basis to maintain physiologic homeostasis and perhaps to prevent the adverse changes in the membrane that occur over time. The anticipated effect of a gene therapy strategy could be measured in maintenance of desired transport characteristics and in patients being able to remain on the therapy for longer periods of time without the negative outcomes. In summary, the use of a gene therapy strategy to enhance peritoneal dialysis is an innovative and exciting concept with the potential to provide new treatment platforms for patients with end-stage renal disease.

This article has been cited by other articles:

				M. Buemi, C. Aloisi, G. Cutroneo, L. Nostro, and A. Favaloro Flowing time on the peritoneal membrane Nephrol. Dial. Transplant., January 1, 2004; 19(1): 26 - 29. [Full Text] [PDF]

				J. Ni, P. Moulin, P. Gianello, O. Feron, J.-L. Balligand, and O. Devuyst Mice that Lack Endothelial Nitric Oxide Synthase Are Protected against Functional and Structural Modifications Induced by Acute Peritonitis J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3205 - 3216. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673